Register now!

Patients all over the world should benefit from the achievements of predictive medicine and the introduction of in silico clinical trials (ISCTs), which promise the accelerated and safe introduction of new products such as medical devices or pharmaceuticals to the market place. These concepts cannot be developed by academics or in industry alone, and ultimately they need to be accepted by regulatory agencies around the world. When regulators accept simulation augmented submissions, and agree upon a common model credibility assessment philosophy will patients benefit from the utilization of in silico medicine. 

The objective of the Avicenna Alliance International Working Group is the promotion of the benefits of predictive medicine and ISCTs through the global connections of experts from academia, industry, and regulatory agencies. Together we will work on developing objective standards, increasing confidence in in silico methods and their acceptance in support of regulatory approval process.

Avicenna Alliance news

And the EMA goes to… Amsterdam!

During a General Affairs Council meeting on 20 November, the EU27 ministers decided on the new location of the European Medicines Agency (EMA) and the European Banking...

find out more ›

Commission adopts 2018 Work Programme

Following on from the announcements made in President Juncker's 2017 State of the Union Address, the European Commission adopted on 24 October 2017 its 2018 Work...

find out more ›

Avicenna Alliance interview for ANSYS

For the Avicenna Alliance, in silico medicine is the obvious connect between the promise of big data and the need for personalised medicine. In an interview for...

find out more ›

Show all activites